Literature DB >> 23323521

Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly.

Shu Liu1, Padmavathy Nandha Premnath, Joshua K Bolger, Tracy L Perkins, Lindsay O Kirkland, George Kontopidis, Campbell McInnes.   

Abstract

A major challenge in drug discovery is to develop and improve methods for targeting protein-protein interactions. Further exemplification of the REPLACE (REplacement with Partial Ligand Alternatives through Computational Enrichment) strategy for generating inhibitors of protein-protein interactions demonstrated that it can be used to optimize fragment alternatives of key determinants, to combine these in an effective way, and this was achieved for compounds targeting the cyclin-dependent kinase 2 (CDK2) substrate recruitment site on the cyclin regulatory subunit. Phenylheterocyclic isosteres replacing a critical charge-charge interaction provided new structural insights for binding to the cyclin groove. In particular, these results shed light onto the key contributions of a H-bond observed in crystal structures of N-terminally capped peptides. Furthermore, the structure-activity relationship of a bis(aryl) ether C-terminal capping group mimicking dipeptide interactions was probed through ring substitutions, allowing increased complementarity with the primary hydrophobic pocket. This study further validates REPLACE as an effective strategy for converting peptidic compounds to more pharmaceutically relevant compounds.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23323521      PMCID: PMC3692612          DOI: 10.1021/jm3013882

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  21 in total

Review 1.  Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control.

Authors:  Thomas Oelgeschläger
Journal:  J Cell Physiol       Date:  2002-02       Impact factor: 6.384

Review 2.  Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit.

Authors:  Campbell McInnes; Martin J I Andrews; Daniella I Zheleva; David P Lane; Peter M Fischer
Journal:  Curr Med Chem Anticancer Agents       Date:  2003-01

3.  Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes.

Authors:  Martin J I Andrews; Campbell McInnes; George Kontopidis; Lorraine Innes; Angela Cowan; Andy Plater; Peter M Fischer
Journal:  Org Biomol Chem       Date:  2004-09-09       Impact factor: 3.876

Review 4.  To cycle or not to cycle: a critical decision in cancer.

Authors:  M Malumbres; M Barbacid
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

5.  A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases.

Authors:  A K Ghose; V N Viswanadhan; J J Wendoloski
Journal:  J Comb Chem       Date:  1999-01

6.  Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A.

Authors:  D I Zheleva; C McInnes; A-L Gavine; N Z Zhelev; P M Fischer; D P Lane
Journal:  J Pept Res       Date:  2002-11

7.  Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth.

Authors:  Nerissa Mendoza; Sharon Fong; Jim Marsters; Hartmut Koeppen; Ralph Schwall; Dineli Wickramasinghe
Journal:  Cancer Res       Date:  2003-03-01       Impact factor: 12.701

8.  Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype.

Authors:  Campbell McInnes; Kara Estes; Merissa Baxter; Zhengguan Yang; Doaa Boshra Farag; Paul Johnston; John S Lazo; Jianjun Wang; Michael D Wyatt
Journal:  Mol Cancer Ther       Date:  2012-07-30       Impact factor: 6.261

9.  Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange.

Authors:  George Kontopidis; Martin J I Andrews; Campbell McInnes; Angela Cowan; Helen Powers; Lorraine Innes; Andy Plater; Gary Griffiths; Dougie Paterson; Daniella I Zheleva; David P Lane; Stephen Green; Malcolm D Walkinshaw; Peter M Fischer
Journal:  Structure       Date:  2003-12       Impact factor: 5.006

10.  Synthesis and in vitro antimycobacterial activity of novel 3-(1H-pyrrol-1-yl)-2-oxazolidinone analogues of PNU-100480.

Authors:  Gianluca Sbardella; Antonello Mai; Marino Artico; Roberta Loddo; Maria Grazia Setzu; Paolo La Colla
Journal:  Bioorg Med Chem Lett       Date:  2004-03-22       Impact factor: 2.823

View more
  9 in total

1.  Targeting the cyclin-binding groove site to inhibit the catalytic activity of CDK2/cyclin A complex using p27(KIP1)-derived peptidomimetic inhibitors.

Authors:  Arumugasamy Karthiga; Sunil Kumar Tripathi; Ramasamy Shanmugam; Venkatesan Suryanarayanan; Sanjeev Kumar Singh
Journal:  J Chem Biol       Date:  2014-09-18

2.  Efficient soluble expression of active recombinant human cyclin A2 mediated by E. coli molecular chaperones.

Authors:  Asterios I Grigoroudis; Campbell McInnes; Padmavathy Nandha Premnath; George Kontopidis
Journal:  Protein Expr Purif       Date:  2015-05-06       Impact factor: 1.650

3.  Fragment based discovery of arginine isosteres through REPLACE: towards non-ATP competitive CDK inhibitors.

Authors:  Padmavathy Nandha Premnath; Shu Liu; Tracy Perkins; Jennifer Abbott; Erin Anderson; Campbell McInnes
Journal:  Bioorg Med Chem       Date:  2013-11-07       Impact factor: 3.641

4.  Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy.

Authors:  Padmavathy Nandha Premnath; Sandra N Craig; Shu Liu; Campbell McInnes
Journal:  Bioorg Med Chem Lett       Date:  2016-06-10       Impact factor: 2.823

5.  Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.

Authors:  Padmavathy Nandha Premnath; Sandra Craig; Campbell McInnes
Journal:  J Vis Exp       Date:  2015-10-26       Impact factor: 1.355

6.  Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity.

Authors:  Padmavathy Nandha Premnath; Sandra N Craig; Shu Liu; Erin L Anderson; Asterios I Grigoroudis; George Kontopidis; Tracy L Perkins; Michael D Wyatt; Douglas L Pittman; Campbell McInnes
Journal:  J Med Chem       Date:  2014-12-17       Impact factor: 7.446

Review 7.  New Advances in Targeted Therapy of HER2-Negative Breast Cancer.

Authors:  Junsha An; Cheng Peng; Xiaofang Xie; Fu Peng
Journal:  Front Oncol       Date:  2022-03-04       Impact factor: 6.244

8.  Identification of β-strand mediated protein-protein interaction inhibitors using ligand-directed fragment ligation.

Authors:  Zsófia Hegedüs; Fruzsina Hóbor; Deborah K Shoemark; Sergio Celis; Lu-Yun Lian; Chi H Trinh; Richard B Sessions; Thomas A Edwards; Andrew J Wilson
Journal:  Chem Sci       Date:  2021-01-06       Impact factor: 9.825

9.  Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor.

Authors:  Merissa Baxter; Danda Chapagai; Sandra Craig; Cecilia Hurtado; Jessy Varghese; Elmar Nurmemmedov; Michael D Wyatt; Campbell McInnes
Journal:  ChemMedChem       Date:  2020-04-28       Impact factor: 3.540

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.